Alteration of MicroRNA Expression in Lymphocytes in Patients with First-episode Schizophrenia

Overview

Journal BMC Psychiatry

Publisher Biomed Central

Specialty Psychiatry

Date 2025 Mar 7

PMID 40055650

Authors

Jingjing Huang

Xuyi Wang

Affiliations

Soon will be listed here.

Abstract

Background: The development of schizophrenia is related to a combination of genetic and epigenomic factors. MicroRNAs (miRNAs) play a crucial role in epigenetic processes and are relevant to the onset and progression of schizophrenia. They can regulate target genes during the growth and development of neurons and can be affected by genetic and environmental factors associated with schizophrenia. Although prior studies have found abnormal miRNA expression in schizophrenia, few studies have examined the miRNA level in first-episode schizophrenia (FES). The present study aimed to examine the expression of lymphocyte microRNA (miR-107, miR-181a, miR-181b, miR-223, miR-219, miR-137, miR-125b) in patients with first-episode schizophrenia who had never been treated.

Method: We investigated the expression of miRNAs using the real-time polymerase chain reaction (RT-PCR) technology. The severity of clinical symptoms was assessed using Positive and Negative Syndrome Scale (PANSS). The prognostic value of biomarkers was analyzed using receiver operating characteristic (ROC) curves, and the predictive value of these biomarkers was also compared. Logistic regression analysis was used to assess the relative risk related to microRNA alteration in schizophrenia. Logistic regression analyses were then performed to identify the most significant and sensitive miRNA biomarkers.

Results: Compared with the control group, the patient group exhibited significantly higher levels of expression for six miRNAs (miR-181a, miR-137, miR-223, miR-107, miR-181b, and miR-125b) (P < 0.05). The ROCs indicated that miR-223 exhibited the highest diagnostic value, with an area under the curve being 0.916.

Conclusions: The present study provided some insights into the alteration of miRNA expression, which might improve our understanding of the complex global changes in gene expression in the pathophysiology of schizophrenia. This study identified six miRNAs (miR-223, miR-181a, miR-181b, miR-125b, miR-219, and miR-107) that might facilitate the diagnosis of schizophrenia.

References

Smigielski L, Jagannath V, Rossler W, Walitza S, Grunblatt E . Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings. Mol Psychiatry. 2020; 25(8):1718-1748. DOI: 10.1038/s41380-019-0601-3. View

Moreau M, Bruse S, Jornsten R, Liu Y, Brzustowicz L . Chronological changes in microRNA expression in the developing human brain. PLoS One. 2013; 8(4):e60480. PMC: 3628885. DOI: 10.1371/journal.pone.0060480. View

Soares-Weiser K, Maayan N, Bergman H, Davenport C, Kirkham A, Grabowski S . First rank symptoms for schizophrenia. Cochrane Database Syst Rev. 2015; 1:CD010653. PMC: 7079421. DOI: 10.1002/14651858.CD010653.pub2. View

He E, Lozano M, Stringer S, Watanabe K, Sakamoto K, den Oudsten F . MIR137 schizophrenia-associated locus controls synaptic function by regulating synaptogenesis, synapse maturation and synaptic transmission. Hum Mol Genet. 2018; 27(11):1879-1891. PMC: 5961183. DOI: 10.1093/hmg/ddy089. View

Saba R, Storchel P, Aksoy-Aksel A, Kepura F, Lippi G, Plant T . Dopamine-regulated microRNA MiR-181a controls GluA2 surface expression in hippocampal neurons. Mol Cell Biol. 2011; 32(3):619-32. PMC: 3266602. DOI: 10.1128/MCB.05896-11. View

Kimoto S, Glausier J, Fish K, Volk D, Bazmi H, Arion D . Reciprocal Alterations in Regulator of G Protein Signaling 4 and microRNA16 in Schizophrenia. Schizophr Bull. 2015; 42(2):396-405. PMC: 4753606. DOI: 10.1093/schbul/sbv139. View

Zhang Y, Fan M, Wang Q, He G, Fu Y, Li H . Polymorphisms in MicroRNA Genes And Genes Involving in NMDAR Signaling and Schizophrenia: A Case-Control Study in Chinese Han Population. Sci Rep. 2015; 5:12984. PMC: 4530343. DOI: 10.1038/srep12984. View

Chen B, Lin J, Lu M, Tan H, Jang F, Lin S . Neurodevelopment regulators miR-137 and miR-34 family as biomarkers for early and adult onset schizophrenia. NPJ Schizophr. 2021; 7(1):35. PMC: 8257739. DOI: 10.1038/s41537-021-00164-1. View

Beveridge N, Tooney P, Carroll A, Gardiner E, Bowden N, Scott R . Dysregulation of miRNA 181b in the temporal cortex in schizophrenia. Hum Mol Genet. 2008; 17(8):1156-68. DOI: 10.1093/hmg/ddn005. View

10.

Lai C, Yu S, Hsieh M, Chen C, Chen H, Wen C . MicroRNA expression aberration as potential peripheral blood biomarkers for schizophrenia. PLoS One. 2011; 6(6):e21635. PMC: 3126851. DOI: 10.1371/journal.pone.0021635. View

11.

Song H, Sun X, Zhang L, Zhao L, Guo Z, Fan H . A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment. J Psychiatr Res. 2014; 54:134-40. DOI: 10.1016/j.jpsychires.2014.03.008. View

12.

Liang Y, Ridzon D, Wong L, Chen C . Characterization of microRNA expression profiles in normal human tissues. BMC Genomics. 2007; 8:166. PMC: 1904203. DOI: 10.1186/1471-2164-8-166. View

13.

Schmitt A, Martins-de-Souza D, Akbarian S, Cassoli J, Ehrenreich H, Fischer A . Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms. World J Biol Psychiatry. 2016; 18(5):330-356. DOI: 10.1080/15622975.2016.1224929. View

14.

Geaghan M, Cairns M . MicroRNA and Posttranscriptional Dysregulation in Psychiatry. Biol Psychiatry. 2015; 78(4):231-9. DOI: 10.1016/j.biopsych.2014.12.009. View

15.

Lai C, Lee S, Scarr E, Yu Y, Lin Y, Liu C . Aberrant expression of microRNAs as biomarker for schizophrenia: from acute state to partial remission, and from peripheral blood to cortical tissue. Transl Psychiatry. 2016; 6:e717. PMC: 5068884. DOI: 10.1038/tp.2015.213. View

16.

Harraz M, Eacker S, Wang X, Dawson T, Dawson V . MicroRNA-223 is neuroprotective by targeting glutamate receptors. Proc Natl Acad Sci U S A. 2012; 109(46):18962-7. PMC: 3503176. DOI: 10.1073/pnas.1121288109. View

17.

Coyle J . Glutamate and schizophrenia: beyond the dopamine hypothesis. Cell Mol Neurobiol. 2006; 26(4-6):365-84. PMC: 11881825. DOI: 10.1007/s10571-006-9062-8. View

18.

van den Berg M, Krauskopf J, Ramaekers J, Kleinjans J, Prickaerts J, Briede J . Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. Prog Neurobiol. 2019; 185:101732. DOI: 10.1016/j.pneurobio.2019.101732. View

19.

Zhao Y, Zhang K, Jiang H, Du J, Na Z, Hao W . Decreased Expression of Plasma MicroRNA in Patients with Methamphetamine (MA) Use Disorder. J Neuroimmune Pharmacol. 2016; 11(3):542-8. DOI: 10.1007/s11481-016-9671-z. View

20.

Yao Q, Chen Y, Zhou X . The roles of microRNAs in epigenetic regulation. Curr Opin Chem Biol. 2019; 51:11-17. DOI: 10.1016/j.cbpa.2019.01.024. View